Fulgent Genetics, Inc. (FLGT) Stock Price & Analysis
Fulgent Genetics, Inc. (FLGT) is trading at USD 20.1, up 0.55% today, as of October 23, 2026 at 15:51 UTC (US market open; quotes may be delayed), according to Nexqual market data.
FLGT last closed at USD 19.99; today's session has ranged USD 19.65–20.23 on volume of 41,602 shares. Market capitalization is $553.06M, with a 52-week range of USD 13.46–31.04 (NGM). Source: Nexqual, retrieved October 23, 2026 at 15:52 UTC.
Also available as compact Markdown for AI agents: nexqual.com/FLGT.md
Key facts (FLGT)
- Last four reported quarters (through Jun 30, 2026): revenue $324M, net income -$84.4M (-26.0% margin), free cash flow -$104M (SEC filings).
- Analysts: Hold (mean 3.00 on a 1–5 scale) (1 analysts), mean target USD 19 (range 19–19).
- Total return with dividends: 1Y -14.9% vs S&P 500 +14.7%; 5Y -75.8% vs S&P 500 +77.4%.
- Next earnings: 2026-11-05, EPS estimate USD -0.65, revenue estimate $86.3M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (FLGT)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $993M | $619M | $289M | $283M | $323M | $324M |
| Gross profit | $777M | $367M | $104M | $107M | $131M | — |
| Operating income | $676M | $179M | -$196M | -$73.9M | -$91.1M | -$122M |
| Net income | $507M | $143M | -$168M | -$42.7M | -$60.5M | -$84.4M |
| Free cash flow | $515M | $235M | $4.8M | -$19.3M | -$124M | -$104M |
| Gross margin | 78.3% | 59.3% | 36.1% | 37.8% | 40.6% | — |
| Operating margin | 68.1% | 28.8% | -67.6% | -26.1% | -28.2% | -37.7% |
| Net margin | 51.1% | 23.2% | -58.0% | -15.1% | -18.8% | -26.0% |
| Revenue growth | +135.4% | -37.6% | -53.3% | -2.0% | +13.8% | — |
| Cash + short-term investments | — | — | $97.5M | $258M | $336M | — |
| Total debt | — | $3.4M | $3.0M | $2.5M | $2.0M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (FLGT)
P/S 1.7x · EV/Sales 0.9x · P/B 0.6x · FCF yield -18.77% · Earnings yield -15.26% · Buyback yield (TTM) 11.55% · Net cash $256M · EV $298M
Analysts (FLGT)
Consensus Hold (mean 3.00 on a 1–5 scale), 1 analysts; mean target USD 19 (low 19, high 19).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-04 | Piper Sandler | Target raised | Neutral | $15 → $19 |
Total return (dividends reinvested) (FLGT)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -14.9% | -75.8% |
| S&P 500 (SPY) | +14.7% | +77.4% |
| Per year | -14.9% | -24.7% |
| Volatility (annualized) | 67.4% | 49.5% |
| Max drawdown | -55.3% (Nov 2025→Mar 2026) | -86.0% (Dec 2021→Apr 2026) |
FLGT revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Laboratory Services | $85.4M | 100.0% | +4.3% |
| Therapeutic Development | $30,000 | 0.0% | — |
| Total revenue | $85.4M | 100% | — |
FLGT revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $78.3M | 91.7% | +2.7% |
| Non Us | $7.1M | 8.3% | +26.8% |
| Other Countries | $4.0M | 4.7% | +26.8% |
| China | $3.1M | 3.6% | +28.0% |
| Total revenue | $85.4M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
FLGT suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | ILLUMINA, INC. (ILMN) | “In particular, we rely on Illumina Inc., or Illumina, as the sole supplier of the next generation sequencers and associated reagents we use to perform our genetic tests and as the sole provider of maintenance and repair services for these sequencers; on Roche Holdings AG for certain laboratory equipment, supplies, and services for our immunohistochemistry services; on Leica Biosystems for an automated digital scan…” |
| Supplier | Roche Holdings | “In particular, we rely on Illumina Inc., or Illumina, as the sole supplier of the next generation sequencers and associated reagents we use to perform our genetic tests and as the sole provider of maintenance and repair services for these sequencers; on Roche Holdings AG for certain laboratory equipment, supplies, and services for our immunohistochemistry services; on Leica Biosystems for an automated digital scan…” |
| Customer | Laboratory | “Our Laboratory Services Customers” |
| Partner | ANP Technologies | “Previously, in June 2017, we entered into an exclusive license agreement with ANP Technologies, Inc., or ANP, as amended on December 28, 2017, and May 1, 2024.” |
Quoted from the company's 10-K filed Feb 27, 2026.
FLGT customer concentration
In the period ended Jun 30, 2026, a single direct customer accounted for 10% of revenue, per the company's 10-Q filed Jul 30, 2026. The company does not name it.
FLGT company outlook (results filed Jul 30, 2026)
- “This number further assumes receipt of approximately $106.1 million in tax refunds prior to December 31, 2026, which have been delayed as a result of constrained resources at the IRS; and assumes capital purchases of $12 million, no further repurchases under the stock repurchase program, and spend on the therapeutic development business of $26 million.”
Quoted word-for-word from the SEC 8-K results press release.
FLGT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.65 | $0.00 | — | $86.3M | 1 |
| Next quarter (ends Dec 2026) | $-0.69 | $0.00 | — | $88.9M | 1 |
| Current fiscal year (ends Dec 2026) | $-2.27 | $0.00 | — | $331.7M | 1 |
| Next fiscal year (ends Dec 2027) | $-1.38 | $0.00 | — | $382.7M | 1 |
FLGT options: expected move
Options price a move of about ±21.5% (±$4.30) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±14.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 95.5% | ±21.5% |
| Jan 15, 2027 | 84 | 58.0% | ±22.4% |
| Apr 16, 2027 | 175 | 60.6% | ±33.3% |
30-day implied volatility 60.3% vs 44.3% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 15:52 UTC)
| Price | USD 20.1 |
|---|---|
| Change | ▲ 0.55% (up) |
| Previous Close | USD 19.99 |
| Open | USD 19.85 |
| Day Range | USD 19.65 – 20.23 |
| 52-Week Range | USD 13.46 – 31.04 |
| Volume | 41,602 shares |
| Market Cap | $553.06M |
| Exchange | NGM |
Technical Analysis (FLGT)
Nexqual's technical model rates FLGT "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 15:52 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.72 (neutral) |
| vs SMA50 | Below (USD 20.58) |
| MACD | -0.22 (negative) |
Analyst Ratings (FLGT)
Wall Street analysts rate FLGT "Hold" based on 1 analysts, with a mean price target of USD 19 (range USD 19–19), per Nexqual as of October 23, 2026 at 15:52 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 19 |
| High Target | USD 19 |
| Low Target | USD 19 |
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (FLGT)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.65 |
| Revenue Estimate | $86.30M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.58 vs est -0.44 ▼ miss |
| 2026-03-31 | USD -0.36 vs est -0.35 ▼ miss |
| 2025-12-31 | USD 0.16 vs est 0.03 ▲ beat |
| 2025-09-30 | USD 0.14 vs est -0.22 ▲ beat |
Source: Nexqual, October 23, 2026 at 15:52 UTC.
Financials & Fundamentals (FLGT)
| Total Revenue | $323.93M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +4.40% |
| Gross Margin | +35.58% |
| Operating Margin | -39.35% |
| Profit Margin | -26.05% |
| ROE | -8.11% |
| Debt / Equity | 0.01 |
| Current Ratio | 6.34 |
| Total Cash | $257.03M |
| Total Debt | $9.60M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$103.79M (-32.0% of revenue) |
Source: Nexqual, October 23, 2026 at 15:52 UTC.
Financial Health Score (FLGT)
Nexqual rates Fulgent Genetics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 15:52 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 36%, operating -39% (last 12 months) |
| Balance Sheet | Strong — $257M cash and investments vs $1M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$104M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -8%, ROA -6.3% |
Ownership (FLGT)
| Insider Ownership | +37.75% |
|---|---|
| Institutional Ownership | +58.13% |
| Shares Outstanding | 27.52M |
| Float | 16.69M |
| Short % of Float | +13.06% |
Source: Nexqual, October 23, 2026 at 15:52 UTC.
Leadership (FLGT)
Fulgent Genetics, Inc. is led by Ming Hsieh, Chairman & CEO, per Nexqual as of October 23, 2026 at 15:52 UTC.
| Chairman & CEO | Ming Hsieh |
|---|---|
| COO & President | Jian Xie |
| Chief Financial Officer | Paul Kim |
| Chief Scientific Officer & Lab Director | Hanlin Gao D.A.B.M.G., FACMG |
| Vice President of Operations & Compliance | Doreen Ng |
Major Backers & Investors (FLGT)
Notable institutional backers of Fulgent Genetics, Inc. include Acadian Asset Management. LLC, Jacobs Levy Equity Management, Inc., JPMorgan, according to Nexqual as of October 23, 2026 at 15:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Acadian Asset Management. LLC | 3.7% |
| Jacobs Levy Equity Management, Inc. | 2.84% |
| JPMorgan | 2.75% |
| Diametric Capital, Lp | 2.54% |
| Ameriprise Financial, Inc. | 2.44% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.31% |
| Vanguard Group | 2.87% |
| Dimensional Fund Advisors | 2.27% |
| Geode Capital | 1.89% |
| State Street | 1.81% |
Source: Nexqual, October 23, 2026 at 15:52 UTC.
From Fulgent Genetics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary technology platform for our laboratory services business includes proprietary gene probes, data suppression and comparison algorithms, AI learning software, and proprietary laboratory information management systems.
- We seek to protect our proprietary technology and processes, and obtain and maintain ownership of certain technologies, in part, through non-disclosure and intellectual property assignment agreements with our employees, consultants, and commercial partners.
- We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems.
- We principally rely on trade secrets and know-how to protect the proprietary technology platform we use in our laboratory services business to develop and maintain our competitive position.
Partnerships
- Previously, in June 2017, we entered into an exclusive license agreement with ANP Technologies, Inc., or ANP, as amended on December 28, 2017, and May 1, 2024.
Legal & Regulatory Risks (Item 1A, quoted)
- Any changes in federal laws, regulations or enforcement policies with respect to the marketing of clinical laboratory tests, or violations of laws or regulations by us, could materially and adversely affect our business, prospects, results of operations or financial condition.
- We are subject to broad legal requirements regarding the information we test and analyze, and any failure to comply with these requirements could result in materially significant, penalties, materially damage our reputation and materially harm our business.
- We conduct business in a heavily regulated industry. Complying with the numerous statutes and regulations pertaining to our business is expensive and time-consuming, and any failure by us, our consultants or commercial partners to comply could result in substantial and material penalties.
- We have and may again be required to modify our business practices, pay fines, incur significant expenses, or experience losses due to litigation, governmental investigations, or as a result of voluntary disclosure processes.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MYGN | Myriad Genetics, Inc. | USD 5.8 | ▲ 0.69% |
| CSTL | Castle Biosciences, Inc. | USD 33.07 | ▼ 0.36% |
| OPK | Opko Health, Inc. | USD 1.62 | ▼ 0.92% |
| FRNM | Freenome, Inc. | USD 12.61 | ▼ 3.78% |
| PSNL | Personalis, Inc. | USD 15.81 | ▼ 0.09% |
| WGS | GeneDx Holdings Corp. | USD 62.96 | ▼ 6.23% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 15:52 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt